Cumulative Genetic Burden Defines a Gradient of Risk in MYBPC3-Related Hypertrophic Cardiomyopathy
Variant / mechanism
MYBPC3
Haploinsufficiency due to a truncating MYBPC3 variant, worsened by an intermediate-effect variant or a second monogenic variant
Summary
Among 11,991 hypertrophic cardiomyopathy probands genotyped at a single centre, 2,767 were genotype-positive; MYBPC3 accounted for 47.6%, with a truncating variant in 81.9% of them. In carriers of a truncating MYBPC3 variant, an additional intermediate-effect variant or a second monogenic variant defined a gradient of severity: median age at diagnosis fell from 48 years in isolated carriers to 42 and then 28 years, and mean wall thickness rose from 21.3 to 24.1 and then 26.3 mm. In multivariable Cox analysis, cumulative genetic burden remained an independent predictor of major adverse cardiovascular events, with the highest risk in carriers of a sarcomeric intermediate-effect variant (HR 10.3) and biallelic MYBPC3 carriers (HR 23.2), estimates based on few events. All biallelic carriers were diagnosed in childhood.
Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.
Analysis
This work provides a quantitative basis for not stopping at the first truncating MYBPC3 variant: a second variant, even of intermediate effect, changes the risk estimate, which raises the question of whether it belongs in the report. Subgroup hazard ratios rest on few events and on a single-centre series of probands; turning them into a surveillance protocol will require replication.
Analysis by Dr Thibaut Benquey
Why this score?
Clinical impact: 2/3 · Evidence strength: 2/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 1/1 → Total: 7/10
Keywords
More articles on MYBPC3
Every Wednesday · Annotated selection · Free · Unsubscribe anytime